Questions or comments? Send us an email.
Leading a New Era of DiscoveryJoin us October 27—28, 2015 More Information Coming Soon

Trainee Entrepreneurship Forum and Networking Reception

This is the second year that we are offering a program developed exclusively for students and postdoctoral trainees associated with the Mount Sinai Health System during the SINAInnovations conference. The program includes a dynamic series of panels, workshops, and a large, popular networking reception. Attendance is free but space is limited and registration is required. We hope that you can join us!

Place: Hess Center for Science and Medicine, 1470 Madison Ave (101st and Madison), 2nd Floor
Date: Tuesday, November 18, 2014
Time: 2:00 PM to 6:00 PM
To Register: Please click here 

Trainee Entrepreneurship Forum

Panel: "How to Create Disruptive Technology in Science and Medicine"
Place: Davis Auditorium
Time: 2:00 PM to 2:45 PM

Workshops: Attend one of three concurrent workshops:

"Transforming Ideas into Technology" — Davis Auditorium
"How to Pitch Yourself and Your Idea" — Seminar Room A
"Funding Beyond the NIH Box" — Seminar Room B

Time: 2:45 PM to 3:30 PM

Lecture: "Career Opportunities and How to Network Your Way into One"
Place: Davis Auditorium
Time: 3:30 PM to 4:00 PM

Medical Student Session: "Personalizing Medical Education for the Future Physician-Innovator"
Place: Davis Auditorium
Time: 4:00 PM - 5:00 PM

Networking Reception

This networking event is designed for students and postdocs to learn about exciting career paths from industry experts. Professionals will be situated at tables where they will discuss their respective fields and what their jobs entail. Students and postdocs will be able to circulate between the tables to network and explore a variety of careers involving science, technology and medicine. Light refreshments will be served.
Sponsors: Graduate School of Biomedical Sciences, the Icahn School of Medicine at Mount Sinai, The Mount Sinai Alumni Association, Office of Alumni and Development, Postdoc Executive Committee, and Women in Science
Place: Hess Center for Science and Medicine, 2nd Floor
Time: 4:00 PM to 6:00 PM

Organizing Committee: Nicole McKnight, PhD, Katharine Seip-Cammack, PhD, Susana Bardina, Brett Marinelli, and Howard Levin, MD

Questions? Please contact Katharine Seip-Cammack, PhD, at:

Featured Speaker Bios
Milena AdamianManaging Partner, Azimuth Ventures
Founder and Executive Director, Life Sciences Angel Network (LSAN)

Dr. Adamian is the Founder and a Managing Partner of Azimuth Ventures, a venture fund focused on early stage healthcare-centric opportunities.

She is also the Founder and Executive director of Life Sciences Angel Network, a predecessor of Azimuth Ventures, that built an ecosystem for early-stage investment activities in medical devices and healthcare information technology coupled with conferences and educational events targeting entrepreneurs and investors.

Dr. Adamian brings a unique perspective of a clinician and academic researcher with genuine passion for breakthrough technologies enriched by industry knowledge, Wall Street, and venture capital experience. During the last 20 years, her career included professional appointments at Interventional Cardiology departments (Lenox Hill Hospital, New York) and Columbus Hospital (Milan, Italy), Medical Director at Boston Scientific Corporation (NYSE: BSC), Equity Analyst, Medical Devices and Supplies at Lehman Brothers and Managing Director, Easton Capital.

She is actively involved with several accelerators and angel groups across the US. Dr. Adamian was named to the TechWeek100 list of leaders in NYC area with significant impact in business and technology.

Her past and present investments and board involvements include Xoft (now NYSE: ICAD), Cardiovascular Systems (now NYSE: CSII), Forge Medical, Precise Light Surgical, Quartzy, Comprehend Systems, ZappRX, Common Sensing, BioTrace Medical, Wellframe, Owlet Care, and SVBio.

Dr. Adamian is a member of the American College of Cardiology and is an author of a number of scientific peer-reviewed articles.

She holds an MSc degree in Biostatistics and Clinical Research Methods from Mailman School of Public Health (Columbia University), and MD and PhD degrees in Clinical Cardiology (Russian Academy of Medical Sciences).
Ashish AtrejaAssistant Professor, Medicine, Gastroenterology at Mount Sinai Hospital
Dr. Ashish Atreja has formal training in epidemiology and board certification in gastroenterology, clinical informatics and internal medicine. Over the last ten years, he has led many informatics initiatives at Cleveland Clinic and Mount Sinai Medical Center that includes developing online education modules, leading EHR implementation in an integrated delivery network, developing registries, secondary use of healthcare data and developing patient and provider facing apps (applications).

As Director of Informatics for Research, Outcomes and Quality (I-ROQ) in the Division of Gastroenterology, Dr. Atreja leads the Sinai AppLab that supports the team's long-term vision of developing Learning HealthCare System in Gastroenterology that will include point-of-care multi-centric registries, apps for care, education and research as well as quality improvement. Through NIH support, he has been able to develop a patient-centric app and physician dashboard, HealthPROMISE (Health Patient Reported Outcomes and Medical Illness Severity Evaluation), where IBD patients longitudinally measure their quality of care as well as quality of life metrics; and physicians utilize this information for collaborative decision making and improving patient outcomes. This platform is now developed and integrated with Electronic Health Record.
Piraye Yurttas BeimFounder and CEO, Celmatix
Piraye Yurttas Beim, PhD, is Founder and CEO of Celmatix, a New York City-based precision medicine company focused on female fertility that was recently named to Crain's "Top Biotech Companies to Watch."

Dr. Beim's embryology research at the University of Cambridge (UK) and doctoral work at Cornell (Weill) on the molecular genetics of mammalian infertility took a very personal turn when she began to notice many of the successful, career-minded women in her network begin to voice strong concerns about their biological clocks. That is when it dawned on her: What if women could understand their own fertility based on data and biology rather than age alone? How would that change how women made life-defining decisions? In that moment, Celmatix was born.

Dr. Beim has also been widely acknowledged as an emerging business leader. She was most recently recognized by Inc. magazine as one of the "10 Women to Watch in Tech," Crain's "40 Under 40," and named both a New York City Venture Fellow by the New York City Economic Development Corporation and a Life Sciences Fellow by the New York Biotechnology Association.
Jerry Castanos3D Heights Bio, CEO
3D Printing

Native New Yorker Jerry Castanos is the founder and owner of 3D Heights. He joined the Army and was Assigned to 1st BN/ 1st Special Forces Group, where he was responsible for property accountability for a Special Forces Battalion valued at $30M. After his military career, he worked on several Department of Defense Army Material Command contracts, including different operations in Dubai, Qatar, Kuwait, Iraq, and Afghanistan. In 2013, Jerry opened 3D Heights, a 3D Printing company which focuses on 3D designing, scanning and printing. Jerry brings passion and dedication to customers who visit 3D Heights in person and online, offering the latest 3D printers and scanners as well as classes in 3D technology.
Hina W. ChaudhryAssociate Professor, Medicine
Director, Cardiovascular Regenerative Medicine
Icahn School of Medicine at Mount Sinai

Hina W. Chaudhry, MD is a cardiologist, scientist, and entrepreneur. She is currently Associate Professor of Medicine and Director of Cardiovascular Regenerative Medicine at Icahn School of Medicine at Mount Sinai. She is also Founder of VentriNova, Inc., a biotech company aimed at developing clinical treatments for cardiac regeneration. Her work has been published in leading scientific/medical journals and she is regularly invited to speak globally on cardiovascular disease, and is an on-air commentator sought by media. She has been awarded some of the highest awards in her field, including Irving Scholar at Columbia University, TEDMED 2013 Innovation Scholar, National Institutes of Health Research Career Award, American Heart Association Clinician-Scientist Award and was the top ranked cardiology fellow in the nation for an NIH National Research Service Award and many others. She holds Bachelor's degrees in Biology and Chemistry from MIT, and an MD with Honors from Harvard Medical School.
Ke ChengFounder and CEO, HistoWiz
Ke Cheng, PhD, is a cancer researcher with expertise in mouse histopathology. She received her PhD in the laboratory of Pier Paolo Pandolfi at Harvard Medical School and led a team of investigators to publish papers in journals including Nature and Blood. Dr. Cheng was a Teaching Fellow at Harvard University, a NCCR Molecular Oncology postdoctoral fellow in the laboratory of Douglas Hanahan at ISREC, and a scientist at a cancer diagnostic company (NASDAQ:CGIX).

During her PhD and postdoctoral studies, Dr. Cheng realized that the current speed of histology and the method of collaboration greatly hinders cancer research progress. She founded HistoWiz to fight cancer cooperatively instead of individually by facilitating collaboration between scientists and pathologists. HistoWiz is a histology service company that processes tissue specimens and digitizes the results for biomedical researchers. It guarantees a three-day turnaround time from wet tissue submission to digital result delivery on a cloud database. It also provides online collaboration features; low-cost, long-term data management; and mouse cancer pathology expertise.

The novel HistoWiz Viewer allows instant global access to digital slides online on any PC, Mac or mobile devices without the need to download additional software or gigabyte-sized files. Dr. Cheng has been invited to give talks at events such as BioInnovation Day in Switzerland, Entrepreneurship Lab at Microsoft, Women in Entrepreneurship at NYU, MIT-CHIEF, and NY Innovation Showcase. Under her leadership, HistoWiz achieved breakeven status after its first month of operation at the Advanced Biotechnology Incubator in NYC and now has more than 200 customers around the world, from universities (such as MSKCC, Cornell, Harvard, MSSM, CINJ, NYU, SUNY Downstate), foundations (such as HHMI, Cancer Research UK, Orentriech), and biotechnology and pharmaceutical companies (such as Alexion, Rigel, Otsuka).
Annetine GelijnsEdmond A. Guggenheim Professor of Health Policy, Icahn School of Medicine at Mount Sinai
An expert in health policy and clinical evaluative research, Annetine Gelijns' cutting-edge research has provided critical insight into the forces that drive the rate and direction of technological change in medicine that promises to improve patient outcomes and reduce health care costs.

As Chair of the Department of Population Health Science and Policy and Co-Director of the International Center for Health Outcomes and Innovation Research (InCHOIR) at Mount Sinai, Dr. Gelijns' research focuses on surgical and device-based trials; comparative effectiveness research; and the factors shaping the development and diffusion of medical technology, and their policy implications. She has written extensively about the uncertainty involved in medical research, the roles of the public and private sectors in technological change, and the dynamics of medical innovation. Her more recent work has focused on the design, execution and policy implications of clinical trials of novel surgical procedures, biologicals and devices. She directed the data coordinating center (DCC) for several NIH- and industry-supported trials as well as the DCC for the NIH- and CIHR-funded Cardiothoracic Surgical Trials Network.

Dr. Gelijns served as a consultant to various national and international organizations, including the WHO, the OECD, Paris, France, the National Academy of Engineering and the Institute of Medicine, and she was a member of the board of the International Society on Technology Assessment in Health Care. She has also authored or co-authored more than 130 peer-reviewed articles, books, book chapters, editorials and reviews.
Joshua GuttmanInstructor, Emergency Medicine
Dr. Guttman completed medical school at McGill University, in Montreal, Canada. He then went on to complete his residency in emergency Medicine at the McGill University Health Center, where he functioned as chief resident. He is currently the point of care ultrasound fellow in the Department of Emergency Medicine's division of Emergency Ultrasound, as well an attending physician and clinical instructor in the department of Emergency Medicine. He is extensively involved in resident point of care ultrasound education across multiple disciplines, as well as medical student point of care ultrasound education. His interests include point of care ultrasound education, critical care ultrasound and point of care ultrasound workflow.
Elma HawkinsPresident, COO, Lion Biotechnologies
Founder, President, Viridian Pharmaceuticals

Dr. Hawkins' 30-year career encompasses pioneering efforts in biotechnology drug development and executive roles in corporate development, strategy, fund raising, and general management. Her therapeutic expertise is in oncology, infectious diseases and wound healing. She started her career at Warner-Lambert/Parke-Davis in Clinical Research. Later she joined the Center for the Study of Drug Development at Tufts Medical School. Following that, she held various positions at BioSurface Technology and Genzyme and was later Vice Chairman of Antigenics. She was also President and CEO of Advanced Viral Research. For the last eight years, she has been consulting for biotechnology companies, venture capital funds and hedge funds. Dr. Hawkins was recently appointed as President and Chief Operating Officer of Lion Biotechnologies. She is also the founder and President of Viridian Pharmaceuticals. Dr. Hawkins has a B.Sc. in Mathematics and Chemistry, B.Sc. (Hons) in Chemistry, M.Sc. in Organic Chemistry, a PhD in Organic Chemistry and an MBA with specialization in entrepreneurship.
Mikail KamalFounder and CEO, Jibon Health Technologies
Mikail Kamal, a Bangladeshi-American who grew up in New York City, has a dual degree in Biomedical Engineering and Mathematics from Columbia University. He is currently pursuing his osteopathic medical degree at Touro College.

Following his strong belief that many public health issues in developing countries can be solved with low-cost solutions, Mr. Kamal founded Jibon Health Technologies in 2012 to address global health problems. Currently, Jibon Health Technologies, in collaboration with a partner organization in Bangladesh, is developing a low-cost and easy-to-use medical device to manage postpartum hemorrhage (PPH), excessive bleeding after child birth. PPH is the leading cause of maternal mortality worldwide, affecting 14 million women and claiming over 150,000 lives annually. Ninety-nine percent of these deaths occur in economically disadvantaged communities, largely due to a lack of available resources and training for midwives. Tampostat™ is a self-regulating, emergency obstetric device designed specifically for use in rural settings, by midwives and birth attendants with minimal medical training.

Among several recognitions, Mr. Kamal and Jibon Health Technologies have received the 2nd prize at 2013 Columbia University Business Plan Competition and the 2nd prize at 2013 NAPEC Innovation Conference. In August of 2014, he received the prestigious $250,000 Saving Lives at Birth Seed Grant, funded by Grand Challenges Canada, USAID, UKAID, The Bill and Melinda Gates Foundation and the Norwegian government to complete phase I and II clinical trials of Tampostat™ in Bangladesh.
Louise LammersAssociate Director, Experimental Therapeutics Institute
Senior Program Manager, 4D Technology Development Program
Icahn School of Medicine at Mount Sinai

Louise Lammers-Johnson, PhD is the Associate Director of the Experimental Therapeutics Institute as well as being the Senior Program Manager for 4D Technology Development Program at the Icahn School of Medicine at Mount Sinai.

Dr. Lammers came to Mount Sinai in 2012 after moving to the United States from the Netherlands. In the Netherlands, she started up and managed a public-private pharma research program at Top Institute Pharma. Prior to this Pharma, she worked for Philips Electronics in several R&D management roles in both Europe and Asia.

Dr. Lammers was a post-doctoral fellow at the Delft University of Technology, The Netherlands and received a PhD in Chemistry (ICI scholarship) from University of Cape Town, South Africa.
Howard LevinCo-founder of Coridea, Inc.
Along with Mark Gelfand, Dr. Howard Levin co-founded Coridea, an idea generator that focuses on the integration of unexploited cardiac, respiratory and renal physiological mechanisms into novel therapeutic solutions for clinical practice. Since its inception in 2003, Coridea has successfully launched or their patents helped launch companies including Ardian, CHF Solutions, eValve and Respicardia (formerly, Cardiac Concepts) that were acquired for more than $1.5 B in total. Dr. Levin received his M.D. from the Icahn School of Medicine at Mount Sinai, his training in cardiology at The Johns Hopkins School of Medicine and was medical director of the LVAD program at Columbia prior to moving into startups. Dr. Levin also has a master's degree in Biomedical Engineering. He is the author on over 50 peer-reviewed scientific publications with 80 issued patents and an additional 100 published patent applications.
Michael MarinProfessor & System Chair, Surgery, Vascular Surgery
Dr. Marin has revolutionized modern vascular surgery. In 1992, in New York, together with Dr. Juan Parodi from Argentina, he performed a minimally invasive repair of an abdominal aortic aneurysm under local anesthesia in an 80 year old man who had multiple medical comorbidities. This event, the first such procedure ever performed in the United States, sparked the rapid development of new treatments by Dr. Marin and other physicians from around the world for the minimally invasive treatment of vascular disease. Application of these techniques and new devices have been extended by Dr. Marin to virtually all areas of arterial vascular disease. Using these minimally invasive stent graft techniques and devices, Dr. Marin performed the world's first minimally invasive repair of popliteal and iliac artery aneurysms and, in 1994, performed the world's first endovascular repair of a ruptured abdominal aortic aneurysm.

Inventions and techniques resulting from Dr. Marin's work formed the basis of 12 important U.S. patents. In 1997, he founded the Teramed Corporation to advance the development and manufacturing of aortic stent graft devices. Teramed was acquired by Johnson & Johnson Corporation in 2001.

An active clinician and teacher, Dr. Marin has contributed extensively to medical literature, including 200 original communications in peer-reviewed journals and more than 60 book chapters. He has served on the editorial boards of the major surgery journals, and has shared his ideas and developments as an invited lecturer throughout the United States and around the world. He has also made over 300 presentations at scientific meetings in the United States and abroad. Additionally, he holds memberships in most regional, national and international professional societies. His achievements have garnered awards from such groups as the American Society of Gastroenterology, The Society for Vascular Surgery and The Peripheral Vascular Surgery Society.
Jason MastaitisScientist, Regeneron Pharmaceuticals
Jason Mastaitis, PhD, was a graduate student at Mount Sinai from 2000-2008 in the laboratory of Dr. Charles Mobbs, where he studied hypothalamic glucose sensing. From there, he went on to Dr. Robert Sherwin's laboratory at Yale University for his postdoctoral fellowship to investigate hypothalamic mechanisms controlling counter-regulatory responses to hypoglycemia.

In 2011, he joined Regeneron Pharmaceuticals as a scientist in their Muscle and Metabolic Disease group. His focus is currently on discovering and developing therapeutics for obesity and Type II diabetes. He currently leads two antibody development programs and functions as in vivo lead on several others. Starting in the fall, he will also be working in collaboration with Columbia University on a human genetics initiative project to discover new and novel human mutations associated with susceptibility to diabetes and obesity.
Shane MayackCo-founder, Executive Director, The Ligo Project
Shane Mayack, PhD, is a scientist interested in removing barriers that exist in the commercialization of scientific innovations, particularly those that could positively impact health. She worked as a Scientific Consultant/Project Manager at Cold Spring Harbor Labs (CSHL) and worked directly with Dr. Jim Watson on initiatives aimed at finding cancer treatments and cures. Much of this work focused on identifying barriers that exist in bringing scientific innovations in cancer treatment to the patient, identifying understudied areas of cancer biology, and coordinating think-tank style meetings at the Banbury Center of CSHL to address the issues.

During her academic training, her research focused on signaling molecules in immune cells that control immune cell fates, including inflammatory immune responses and autoimmunity, as well as studies on hematopoietic stem cell function. Dr. Mayack received her PhD from UMass Memorial Medical Center. She is also a founding member and scientific advisor at Gene-Home Inc.
Stephanie MazlishCo-founder and CEO, The Solution Lab
Stefanie Mazlish, MBA, is Co-founder and CEO of The Solution Lab, a nonprofit start-up which develops creative solutions for health care, pharmaceutical, and biotech companies facing strategic and operational challenges. The Solution Lab forms interdisciplinary teams of students and recent graduates with advanced degrees (PhD/MD/JD/MPH/MBA) to volunteer on management consulting projects in order to gain practical training as well as educational and networking opportunities. The Solution Lab also provides programming for educational workshops and initiatives, with a focus on creative thinking and entrepreneurship.

Ms. Mazlish has a professional background in payer side health care, allied health higher education, and management consulting. She was a semi-finalist in the NYU Stern Social Venture Competition twice, leading start-ups focusing on renewable energy and microfinance; she now judges for the International Impact Investing Challenge. Stefanie earned an MBA from NYU Stern School of Business with specialization in Strategy and Finance, and a BA from The University of Chicago.
Nicole McKnightCo-founder, KiiLN
Nicole McKnight, PhD, is a co-founder of KiiLN (Keystone for Incubating Innovation in Life sciences — NYC), an incubator/accelerator for biotech start-ups in Harlem. KiiLN is a non-profit organization building affordable co-working laboratory space for growing drug discovery companies. Dr. McKnight is dedicated to promoting the growth of the biotech sector in New York City.

Dr. McKnight is a molecular and cell biologist whose twelve years of scientific research have made her well-versed in disease areas, such as cancer and neuroscience; she has also worked with animal models. She has trained at the Harvard Medical School, Cancer Research UK and most recently as a postdoctoral student at the Icahn School of Medicine at Mount Sinai. She found her love of start-ups while working for Gene Logic, Inc., now known as Ore Pharmaceuticals in Cambridge, Massachusetts.

Dr. McKnight received an AB (with honors) from the University of Chicago and a PhD from University College London.
Bryan PazarasManaging Owner, Medical Access Promotions Inc.
Bryan Pazaras, MBA, is the Managing Owner of Medical Access Promotions Inc., a strategy and research business primarily working with the Healthcare Industry to identify and develop business growth. Medical Access Promotions uses Discovery and Qualitative Research processes to identify market and end user insights which are applied in a recommendation-driven, forward focused, and integrated manner. Services have been performed for all sized Companies including Sanofi, Medtronic, and Johnson & Johnson.

Bryan Pazaras received his MBA from St. John's University.
Yaihara Fortis SantiagoProgram Manager, Science Alliance at the New York Academy of Sciences
Yaihara Fortis-Santiago is the Program Manager for the Science Alliance at the New York Academy of Sciences. The Science Alliance offers innovative workshops and courses for early career scientists to develop business, leadership and communication skills.

In 2014, Dr. Fortis completed the Science and Technology Policy Fellowship under the American Association for the Advancement of Science (AAAS). She was assigned to work at the National Science Foundation (NSF) for two years. During her first year, she worked at the Emerging Frontiers in Research and Innovation (EFRI) under the Directorate for Engineering on programs that transform the innovation frontiers of STEM fields using multidisciplinary approaches and inter-institutional collaborations. For her second year, she worked at the Office of Science and Engineering (OISE) on programs that provide international research opportunities for U.S. students and supported the establishment of cooperation agreements within the Americas region.

Dr. Fortis has a long standing commitment to service and mentoring students in STEM fields. For several years she has worked closely with the Society for Advancing Chicanos/Hispanics and Native American in Sciences (SACNAS) and the non-for Profit organization Ciencia Puerto Rico (CienciaPR) to increase the participation of underrepresented minority students in STEM careers. With CienciaPR, she has led several science education efforts to promote contextualization of science in Spanish-speaking regions.

Dr. Fortis obtained her bachelors' degree in Biology from University of Puerto Rico and her doctoral degree in Neuroscience from Brandeis University.
Daniel SeltzerDirector, Center for Technology Innovation and Entrepreneurship
Daniel is the Director of the Center for Technology Innovation and Entrepreneurship at Mount Sinai, where he is running an incubator for BioTech startups, teaching, researching, and building strategic partnerships. Daniel brings over 30 years of experience as an innovative technologist and entrepreneur, working with a wide range of companies and non-profits to develop transformative products and services. As a founder, CTO, board member, mentor and executive, Daniel has built and led organizations in Finance, Education, Health, Media and Publishing, from small startups to Fortune 100s. He has been a guest lecturer and speaker at conferences, and most recently served as CTO of Amplify Learning where he helped create an all-new digital curriculum for middle school using tablets in the classroom.
Geoffrey W. SmithFounding Director of the Mount Sinai Institute of Technology, Icahn School of Medicine at Mount Sinai
Professor, Department of Health Evidence and Policy, Icahn School of Medicine at Mount Sinai

Geoffrey W. Smith is the founding Director of the Mount Sinai Institute of Technology and a Professor of Population Health Science and Policy at the Icahn School of Medicine at Mount Sinai. He is also a co-founder and general partner of Ascent Biomedical Ventures, a venture capital firm focused on early-stage life sciences investments. Having been an active founder, manager, and investor in technology-based companies since 1995, he currently serves on the boards of directors of Azevan Pharmaceuticals, Anterios, BackBeat Medical, Biomerix, Caliber Therapeutics, Coferon, TargAnox, and Vivasure Medical.

Geoff is also a visiting scholar at Rockefeller University, where he founded and directs the university's Science & Economics Program and is an adjunct faculty member at the RU Center for Clinical and Translational Science. He also is a member of the Scientific Advisory Board for Brigham & Women's Hospital in Boston.

Geoff received a B.A. (with honors) from Williams College and a J.D. from the University of Pennsylvania Law School.
Joel WishkovskyCofounder of Sols Systems, Entrepreneur In Residence at Techstars and Director of Sales at Smart Vision Labs
Joel Wishkovsky is an innovative entrepreneur and a leading voice in the healthcare technology, Internet of things and 3D printing spaces. He founded Sols Systems, which is pioneering the use of 3D printing for Orthopedics and Card Gnome, which was an early adopter of digital printing technology. He is the former Entrepreneur in Residence for the Techstars Hardware accelerator, and is an active mentor and advisor for early stage companies with disruptive technology.

Joel is the Director of Sales for Smart Vision Labs whose Smartphone based vision exam aims to provide vision care to >1B people worldwide who lack access.

Previously Joel was part of General Electric's prestigious IT leadership program (IMLP) and it's financial and operational auditing program (Corporate Audit Staff). During his time there he focused on leading large scale IT implementations and doing financial and operational audit work of GE businesses with a specialty around acquisition integrations. Joel is also an avid mountaineer, backpacker and traveler who has visited more than 30 countries and only been excluded from one.
Yun ZhongVP, SunTrust Robinson Humphrey
Yun Zhong joined SunTrust Robinson Humphrey in July 2014 from Cowen and Company, where he had been working as a biotech equity research associate from September 2011. Prior to that, Dr. Zhong was a post-doctoral fellow in the department of neurology at Mount Sinai School of Medicine studying molecular mechanisms of neurodegenerative diseases. Dr. Zhong received a B.S. and an M.S. in biophysical engineering from Osaka University in Japan and a Ph.D. in molecular biology from The Rockefeller University.

View SINAInnovations in a larger map


SINAInnovations Event Address Recommended Parking
Icahn School of Medicine at
Mount Sinai Stern Auditorium
1468 Madison Avenue
(between 99th Sreet and 101st Street)
New York, NY 10029
CSM Underground Parking Garage
10 East 102nd Street
(between Madison Avenue and 5th Ave)
New York, NY 10029
Parking Garage Phone: 212-490-3460